Extracorporeal Support for Patients with Hepatic Failure

  title={Extracorporeal Support for Patients with Hepatic Failure},
  author={Andrew Davenport},
  journal={Hemodialysis International},
  • A. Davenport
  • Published 1 June 2003
  • Medicine
  • Hemodialysis International
Extracorporeal support has been advocated for patients with acute and chronic liver failure. Patients with acute liver failure and those with decompensated cirrhosis can be broadly divided into two groups. The first group comprises those with acute liver failure and ongoing hepatic necrosis, and the second, those with long‐standing chronic decompensation admitted with one or more complications of liver failure, such as encephalopathy without any evidence of a precipitating factor or… 
Blood purification in intensive care patients with multiple organ dysfunction syndrome and sepsis after cardiac surgery
The potential of new extracorporeal molecular technologies allows their successful use in severe cardiac and respiratory failure, acute kidney injury and hepatic dysfunction and in complex therapy for severe infections and sepsis and extreme metabolic violations.
Dialysis-dependent acute kidney injury in children with end-stage liver disease: prevalence, dialysis modalities and outcome
Children with end-stage liver disease have a high risk for dAKI associated with high mortality, and CVVH is associated with better efficacy and less mortality than PD.
Artificial liver support systems.
  • J. George
  • Medicine
    The Journal of the Association of Physicians of India
  • 2004
The various methods of extracorporeal liver support that are available at present are assessed and those that appear to be promising are described.
Bile cast nephropathy: A case report and review of the literature.
The case of bile cast nephropathy and the therapeutic measures undertaken in a middle-aged male with chronic renal insufficiency that developed hyperbilirubinemia and drug-induced liver injury secondary to antibiotic use is reported.
A comparison among three different apheretic techniques for treatment of hyperbilirubinemia
This retrospective observation is one of the largest case series of hepatic failure treated with bilirubin absorption and suggests that PAP could be considered as a first-line approach, in case of kidney involvement.
Полиорганная недостаточность: состояние проблемы и современные методы лечения с использованием низкопоточных мембранных технологий
This analytical literature review generalizes the currently available data on the treatment of multiorgan dysfunction (MOD). The review describes the pathogenesis, triggers, and components of MOD, as


Artificial Hepatic Support
The advent of successful orthotopic liver transplantation for patients with both acute and chronic liver failure has been a major breakthrough in clinical practice, and the number of patients with liver disease awaiting transplantation now exceeds the donation rate.
Artificial liver support devices for fulminant liver failure.
Despite decades of great progress in the field of artificial liver support, no one technique alone yet provides sufficient liver support and a hybrid system seems to be the best option at present.
Acute-on-Chronic Liver Failure: Pathophysiological Basis of Therapeutic Options
This review focusses upon how a precipitant such as an episode of gastrointestinal bleeding or sepsis may start a cascade of events that culminate in end-organ dysfunction and liver failure.
Dialysis in the treatment of renal failure in patients with liver disease.
Overall, the results show that dialysis is only worth attempting in those patients in whom recovery of the underlying liver lesion is possible, and even then treatment for prolonged periods may be necessary.
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.
A bioartificial liver to treat patients with severe liver failure until they can be either transplanted or recover spontaneously and the authors' clinical experience with the BAL has yielded encouraging results.
Powdered sorbent liver dialysis and pheresis in treatment of hepatic failure.
  • S. Ash
  • Medicine
    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • 2001
Liver dialysis resulted in physiologic and neurologic improvement of patients with AHE, regardless of etiology, and may be of clinical benefit in the management of Patients with the most severe hepatic failure and encephalopathy, including patients with FHF or concomitant sepsis.
Long-term survivors with artificial liver support in fulminant hepatic failure.
  • Masakazu Nitta, H. Hirasawa, +9 authors E. Watanabe
  • Medicine
    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • 2002
This suggests that application of ALS in patients with FHF gains time while awaiting transplantation as well as time for functional recovery and regeneration of the liver graft following receipt of the graft with marginal function and/or size.
Liver support by extracorporeal blood purification: A clinical observation
  • J. Stange, S. Mitzner, +12 authors U. Hopt
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2000
It is concluded that in acute excretory failure caused by a chronic liver disease, this treatment provides a therapy option to remove toxins involved in multiorgan dysfunction secondary to liver failure.
The Hepatix extracorporeal liver assist device: initial clinical experience.
The Hepatix ELAD is safe, and it provides measurable metabolic support in patients with late-stage liver failure, and this pilot study provides the impetus to perform controlled trials of ELAD therapy in the treatment of various types of end- stage liver disease.
Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane.
Twenty-one patients with fulminant hepatic failure and coma underwent 180 periods of haemodialysis with polyacrylonitrile membrane (AN 69 HD) and total recovery of consciousness occurred in 17 patients, with an overall figure of 61.5%.